Clinical trial locations
About the trial
PARP inhibitors, such as olaparib, significantly improve progression free survival (PFS) in participants with recurrent, platinum-sensitive high-grade serous/endometrioid ovarian cancer (HGS/EOC), who have a mutation in BRCA 1 or 2 genes. The investigators will test the feasibility of administering a second course of olaparib in participants who have recurrent platinum-sensitive HGS/EOC.
Who can take part?
For women with a recurrence of measureable high grade serous or endometrioid ovarian cancer, fallopian tube or primary peritoneal cancer
Participants who have not been treated with PARP inhibitor previously will be treated with two maintenance courses of olaparib.
Participants, who have received one course of maintenance olaparib before entry to the trial, will only receive one further course of treatment.
Aged 18 or over.
Other criteria will also apply as described by the medical team.
Further information: https://clinicaltrials.gov/ct2/show/study/NCT02855697#contacts